FibroGen’s pamrevlumab disappointing results marks second failure in a row
The Phase III trial for FibroGen’s antibody candidate failed to meet its primary endpoint in children with Duchenne muscular dystrophy.
The Phase III trial for FibroGen’s antibody candidate failed to meet its primary endpoint in children with Duchenne muscular dystrophy.
What's Your Reaction?
